Defence Therapeutics Inc. (CSE: DTC, OTCQB: DTCFF, FSE: DTC), a Montreal-based biotechnology company, has announced it will participate in the 17th World ADC San Diego conference, taking place October 12–15, 2026, in California. The company's CEO will deliver a presentation and fireside discussion on intracellular delivery as a potential next frontier in antibody-drug conjugate (ADC) development. The announcement positions Defence Therapeutics to showcase its proprietary Accum® platform to a global audience of pharmaceutical and biotech leaders, which investors may be watching as a potential catalyst for partnership discussions.

Key Points

  • Defence Therapeutics Inc. (CSE: DTC, OTCQB: DTCFF, FSE: DTC) is a publicly traded Canadian biotechnology company.
  • The company will participate in the 17th World ADC San Diego conference, October 12–15, 2026.
  • CEO Dr. Amie Phinney will present on October 14 at 12:30 p.m.; a scientific poster session is also scheduled for Tuesday afternoon.
  • Investors may be watching for collaboration or partnership opportunities arising from the company's ADC platform presentations.

Defence Therapeutics CEO to Lead Fireside Discussion on ADC Intracellular Delivery

Dr. Amie Phinney, President and Chief Executive Officer of Defence Therapeutics, will take the stage on Wednesday, October 14, at 12:30 p.m. for a presentation and fireside discussion entitled "Beyond Antibody, Linker & Payload – Is Intracellular Delivery the Next Frontier for ADCs?" The session will explore how intracellular trafficking and processing influence ADC activity, whether improving delivery could enhance existing or emerging ADC candidates, and how novel technologies may address these challenges. The release states the session gives Defence an opportunity to contextualise its Accum® platform within the broader evolution of ADC science.

Accum® Scientific Poster to Highlight ADC Trafficking Research

In addition to the on-stage presentation, Defence Therapeutics will present a scientific poster on Tuesday afternoon during the conference poster session. The poster, entitled "Accum: A Plug-In Intracellular Trafficking Platform for Next-Generation ADCs," will be delivered by Dr. Guillaume Lefrançois, Senior Scientist at Defence Therapeutics. The disclosure states the poster will highlight ongoing work evaluating Accum® as an intracellular trafficking platform for ADCs, offering another avenue for the company to engage with researchers and industry peers on its technology's potential applications.

Partnership and Collaboration Engagement Planned Throughout Conference

According to the announcement, the Defence Therapeutics team will be available throughout the four-day event to meet with researchers and representatives from pharmaceutical and biotechnology companies interested in the Accum® platform and the company's ADC-enhancement profiling programmes. World ADC San Diego is described in the release as a leading global forum bringing together innovators, academia, and the clinical community to advance next-generation ADC development. The immediate share price impact was not clear from available public information.